TAGLN2 and bladder transitional cell carcinoma: Additionally, the DFI analysis showed that TAGLN2 methylation acted as a protective marker in KIRC, PAAD, and THCA patients, whereas a detrimental factor for BLCA and STAD (Figure 4F).